Stay updated on Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial
Sign up to get notified when there's something new on the Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial page.

Latest updates to the Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoNo Change Detected
- Check15 days agoChange DetectedA new site revision entry v3.6.6 was added to the change log, and the prior revision v3.6.5 was removed. This indicates a maintenance/patch update to the site, not a change to the study content or functionality.SummaryDifference0.0%

- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedThe page now lists Revision: v3.6.5, replacing the previous Revision: v3.6.4. This indicates a minor update to the page's versioning information.SummaryDifference0.0%

- Check50 days agoChange DetectedThe page's revision tag was updated from v3.6.3 to v3.6.4, indicating a newer version of the page content. This reflects an update to the page text or layout.SummaryDifference0.0%

- Check72 days agoChange DetectedA newer revision identifier appears on the page, indicating a backend or template update; the study content and user-facing information remain unchanged.SummaryDifference0.0%

- Check79 days agoChange DetectedThe page revision label has been updated from v3.6.0 to v3.6.2, indicating a newer version of the ClinicalTrials.gov study page.SummaryDifference0.0%

- Check93 days agoChange DetectedThe study page now indicates recruitment is closed and results have been posted. New navigation/help sections were added (How to Read a Study Record, Common Questions, How to Join a Study), and the 28-day treatment cycle duration is stated.SummaryDifference6%

Stay in the know with updates to Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial page.